A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas

@inproceedings{Hadjadj2017AHA,
  title={A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas},
  author={Djihad Hadjadj and Su-Jung Kim and Thomas Denecker and Laura Ben Driss and Jean-Charles Cadoret and Chrystelle Maric and Giuseppe Baldacci and Fabien Fauchereau},
  booktitle={Aging},
  year={2017}
}
High proliferation rate and high mutation density are both indicators of poor prognosis in adrenocortical carcinomas. We performed a hypothesis-driven association study between clinical features in adrenocortical carcinomas and the expression levels of 136 genes involved in DNA metabolism and G1/S phase transition. In 79 samples downloaded from The Cancer Genome Atlas portal, high Cyclin Dependent Kinase 6 (CDK6) mRNA levels gave the most significant association with shorter time to relapse and… CONTINUE READING